ALTSTATION.IO

IDEX Corporation (IEX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$214.24

Change

+0.61%

Market Cap

$16.13B

Avg Volume

700.5K

Company Overview

IDEX Corporation (IEX) specializes in providing unique solutions through its three main segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). Their product line includes positive displacement pumps, flow meters, precision fluidics, biocompatible medical devices, firefighting pumps, and various valves and systems. Their customers span multiple industries, including water and wastewater management, life sciences, pharmaceuticals, and fire safety. With a global presence, they operate in North America, Europe, and Asia, among other regions.

IDEX is positioned as a market leader in specialty industrial machinery, thanks to its diverse product offerings and robust customer base. The company’s edge lies in its technological innovation and high-quality manufacturing processes. Key competitors include companies like ITT Inc. and Pentair, which also operate in overlapping segments. However, ongoing supply chain challenges and rising raw material costs could pose threats to their growth and margin stability.

Currently, IDEX is in a growth phase, boasting a strong demand for their fluid management and life sciences products. In recent years, they have focused on expanding their portfolio through strategic acquisitions and investments in new technologies. Their recent milestones include enhancing production capabilities and entering new markets, which positions them well for future growth in a competitive landscape.

Key Financials

Market Cap

$16.13B

Revenue

$3.46B

EBITDA

$927.10M

Gross Margin

44.5%

Profit Margin

14.0%

Revenue Growth

4.2%

Total Cash

$580.00M

Total Debt

$1.82B

Free Cash Flow

$560.83M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

33.42

Forward P/E

23.87

Beta

0.98

52-Week High

$217.16

52-Week Low

$153.36

EPS

$6.41

50-Day Avg

$185.05

200-Day Avg

$175.13

Price/Book

3.98

Technical Analysis

The 52-week chart for IDEX Corporation (IEX) clearly shows a bullish trend with a notable increase in price strength since the lows in the $160 range around August and September. The stock has recently rallied from approximately $190 in February, breaking through resistance around $211.37, which now serves as a new key resistance level. Along the way, the price action exhibited consolidation patterns, particularly between April and July, suggesting a buildup before the recent upward momentum. In the last few weeks, the stock has gained further traction, moving to the current price of $214.24, indicating continued positive momentum. Relative to its 52-week range, the current price is approaching significant highs, suggesting a strong bullish sentiment. The 52-week change of 9.3% reflects the market’s confidence, but caution is warranted as it nears potential resistance levels.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for IDEX Corporation (IEX) stock in the past week (February 1-7, 2026):

### 1

IDEX Exceeds Q4 Earnings and Revenue Estimates, Provides 2026 Guidance

Market Update

IDEX Corporation announced its fourth-quarter earnings results on Wednesday, February 4, 2026, reporting adjusted earnings per share (EPS) of $2.10, surpassing the consensus estimate of $2.04. The company’s revenue for the quarter also exceeded expectations, reaching $899.1 million against an estimated $882.0 million, marking a 4.2% increase year-over-year. Following these stronger-than-expected r

Market Sentiment and Analyst Recommendations

Bull Case

IDEX just beat on both earnings and revenue, posting $2.10 adjusted EPS versus $2.04 expected and $899.1M revenue versus $882M guidance. The stock popped 3.5% on the news and is now trading near its 52-week highs, which tells you institutional money believes the beat was real. The Health & Science Technologies segment is showing genuine strength while the company guides for 1-2% organic growth in 2026, which is conservative enough to beat but not so weak it signals trouble. At a P/E of 33.42, the valuation is elevated but not absurd for a company with 13 analyst buy ratings and a $217.54 average price target that implies 1.5% upside from current levels. The balance sheet is solid with $580M cash and a manageable net debt position, giving management flexibility for M&A or shareholder returns. The 52-week chart shows clear bullish momentum from the $160 lows, and the stock breaking through $211 resistance suggests institutional conviction behind this move.

Bear Case

Revenue growth of 4.2% is pedestrian for a company trading at 33x earnings, and the 2026 guidance of just 1-2% organic growth suggests IDEX is slowing down. Two of three segments (FMT and FSDP) are expected to be flat to slightly down, which means the HST strength is doing heavy lifting on a narrowing base. The stock is already at $214.24 near its 52-week highs, leaving limited margin of safety if the company disappoints on Q1 earnings or revises guidance downward. At $16.13B market cap with $1.82B in debt, the company carries meaningful leverage that could become a problem if organic growth doesn’t accelerate. The analyst price target range is wide ($170-$250), indicating real disagreement on fair value, and some recent target cuts (DA Davidson went to $195) suggest not everyone is convinced this beat is sustainable. Valuation compression risk is real if growth doesn’t materialize or if the Fed keeps rates higher for longer.

What to Watch

The critical metric is Q1 2026 organic growth, which the company guided to “about 1%” — beat that and the bull case holds, miss it and expect a 5-10% pullback. Monitor segment performance closely: HST needs to accelerate beyond what’s currently priced in, and FMT and FSDP need to stop deteriorating. Watch the gross margin trend in upcoming quarters; if the company is buying growth through price cuts or losing pricing power, that’s a red flag. The stock is sitting on $211.37 as a resistance level, so if it breaks above $217 convincingly, expect another leg higher toward the $230+ target. Conversely, any drop below $200 would signal that the January-February rally was just a relief bounce. Finally, track M&A activity — IDEX has cash and debt capacity, so any major acquisition announcement could be a positive catalyst, but overpaying would destroy shareholder value given the valuation already embedded in the stock.

Analyst Consensus

BUY

Based on 13 analyst opinions

Low Target

$170.00

Mean Target

$217.54

High Target

$250.00

Earnings and Financial Data

Sector

Industrials

Industry

Specialty Industrial Machinery

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$6.41

Dividend Yield

133.0%

Payout Ratio

44.0%

Frequently Asked Questions

Is IDEX Corporation (IEX) a good stock to buy?

Yes, IEX has a solid analyst recommendation of BUY with a target price of $217.54. The stock is currently trading at $214.24, indicating minimal upside potential, but its strong fundamentals justify a buy.

What is IEX’s price target?

The target price for IEX is $217.54 according to analysts. This suggests a small potential upside from its current trading price of $214.24.

Does IEX pay a dividend?

Yes, IEX offers a dividend yield of 133.0%. This makes it an attractive option for income-focused investors.

What is IEX’s P/E ratio compared to its forward P/E?

IEX has a P/E ratio of 33.42 and a forward P/E of 23.87. This indicates a potential for future growth as the forward P/E is significantly lower.

What has been IEX’s 52-week trading range?

IEX’s stock price has fluctuated between $153.36 and $217.16 over the past year. Trading near the upper end of this range indicates strong investor confidence.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.